Helicobacter pylori infection and the use of NSAIDs

Best Practice and Research: Clinical Gastroenterology

Volumn 15, Issue 5, 2001, Pages 775-785

  Bazzoli, Franco ^a   De Luca, Luca ^a   Graham, David Y ^b  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Anti secretory therapy; Duodenal ulcer; Gastric ulcer; Helicobacter pylori; NSAIDs; Peptic ulcer

Indexed keywords

ANTIBIOTIC AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROTON PUMP INHIBITOR; RANITIDINE; ROFECOXIB;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SAFETY; DRUG USE; ERADICATION THERAPY; GASTROINTESTINAL HEMORRHAGE; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; LONG TERM CARE; OSTEOARTHRITIS; PATHOPHYSIOLOGY; PEPTIC ULCER; RHEUMATOID ARTHRITIS; ULCER HEALING;

EID: 0034756322     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.2001.0234     Document Type: Article

References (63)

1. Non steroidal anti-inflammatory drugs and peptic ulcers
2. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs
3. What consideration should be given to Helicobacter pylori in treating nonsteroidal anti-inflammatory drug ulcers?
4. The epidemiology of Helicobacter pylori infection
5. Does Helicobacter pylori status affect nonsteroidal anti-inflammatory drug-associated gastroduodenal pathology?
6. Helicobacter pylori infection and development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy
7. Norsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients
8. Helicobacter pylori and the relation to other risk factors in patients with acute bleeding peptic ulcer
9. Influence of H. pylori infection and/or low dose aspirin on gastroduodenal ulceration in patients treated with placebo, celecoxib or NSAIDS
10. Long-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: The role of Helicobacter pylori
11. Nonsteroidal anti-inflammatory drug gastropathy
12. Interactions of risk factors for peptic ulcer bleeding
13. Peptic ulcer bleeding: Accessory risk factors and interactions with non-steroidal anti-inflammatory drugs
14. Helicobacter pylori and risk of ulcer bleeding among users of nonsteroidal anti-inflammatory drugs: A case-control study
15. Interaction between Helicobacter pylori and non-steroidal anti-inflammatory drugs in peptic ulcer bleeding
16. Helicobacter pylori increases the risk of peptic ulcer bleeding: A case-control study
17. H. pylori infection increases the risk of nonsteroidal anti-inflammatory drugs-induced gastroduodenal ulceration
18. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs
19. Letter to editor Reply-on dissonances. Helicobacter pylori and NSAIDs
20. Helicobacter pylori enzymes
21. Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats
22. Histological findings in gastric mucosa in patients treated with non-steroidal anti-inflammatory drugs
23. Mechanism of gastrointestinal toxicity of non-steroidal anti-inflammatory drugs
24. Helicobacter pylori up-regulates type 2 cyclooxygenase in gastric epithelial cells
25. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: A controlled double-blind trial
26. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized controlled trial
27. Effect of Helicobacter pylori infection on the severity of gastroduodenal mucosal injury after the acute administration of naproxen or aspirin to normal volunteers
28. Influence of Helicobacter pylori on low dose aspirin (ASA)-induced gastric mucosal injury. A placebo-controlled, double-blind, randomized trial
29. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin
30. Influence of H. pylori and other potential risk factors on clinical gastrointestinal events in a double-blind outcome study of rofecoxib vs. naproxen
31. Severe gastric mucosal damage induced by NSAIDs in healthy subjects is associated with Helicobacter pylori infection and high levels of serum pepsinogens
32. Interrelationships between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and gastroduodenal disease: A prospective study in healthy volunteers
33. Interaction between H. pylori and NSAIDs: Predictive value of density of PMNs, mucosal IL-8 or mucosal and gastric juice nitrite levels on NSAID-induced gastric mucosal injury and ulcer formation
34. Pylori and cag A: Relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications
35. Aspirin and the stomach
36. Gastric mucosa and susceptibility to occult gastrointestinal bleeding caused by aspirin
37. Omeprazole compared with misoprostol for ulcer associated with non steroidal anti-inflammatory drugs
38. A comparison of omeprazole with ranitidine for ulcers associated with non steroidal anti-inflammatory drugs
39. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drugs users
40. NSAID ulcers: Prevalence and prevention
41. Role of Helicobacter pylori infection in NSAID-associated gastropathy
42. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP-NSAIDs study
43. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drugs associated bleeding peptic ulcers? A prospective randomized study
44. Eradication of Helicobacter pylori could not prevent development of gastrointestinal complications in patients requiring long-term low-dose aspirin
45. Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in long-term NSAID users. Response to omeprazole dual therapy
46. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study
47. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse
48. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage
49. Randomised trial of eradication of H. pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers
50. Primary prophylaxis of NSAID-induced gastroduodenal ulcers and dyspepsia in H. pylori (HP)-positive patients: Randomized, double-blind, placebo-controlled treatment of HP infection vs. omeprazole
51. Acute dose of celecoxib, a new specific cycloxigenase-2 (COX-2) inhibitor, do not affect the overall gut permeability
52. Comparison of the effect of rofecoxib (a ciclooxygenase 2 inhibitor), ibuprofen and placebo on the gastroduodenal mucosa of patients with osteoarthritis
53. A randomized trial comparing the effect of rofecoxib, a ciclooxygenase 2 inhibitor, with that or ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis
54. Celecoxib is associated with a significantly lower incidence of clinically significant upper gastrointestinal (UGI) events in osteoarthritis (OA) and rheumatoid arthritis (RA) patients as compared to NSAIDs
55. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis
56. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial
57. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice
58. Systemic biosynthesis of prostacyclin by ciclooxygenase (COX)-2: The human pharmacology of a selective inhibitor of COX-2
59. Chemoprevention of colorectal cancer
60. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor against colon carcinogenesis
61. Colorectal cancer chemoprevention: Aspirin, other NSAID and COX-2 inhibitors
62. The relationship between cyclooxygenase-2 expression and colorectal cancer
63. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis